^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Thyroid Gland Anaplastic Carcinoma
    Drug Class:BRAF inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    Facilitating rapid precision oncology in anaplastic thyroid cancer: Clinical implications of next generation sequencing (NGS) mutation testing and impact on survival.

    Published date:
    05/16/2018
    Excerpt:
    Twenty-four of 51 (47%) BRAFV600E+ pts were treated with a BRAF inhibitor. In BRAF V600E+ patients, BRAF inhibitor treatment was significantly associated with improved OS at 1 year (HR 0.25, 95% CI 0.08-0.78, p = 0.018).
    DOI:
    10.1200/JCO.2018.36.15_suppl.6023
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Natl Compr Canc Netw
    Title:

    BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma

    Excerpt:
    CONTRADICTING EVIDENCE: We report 2 cases of BRAF(V600E)-positive ATC treated with a BRAF inhibitor….A 67-year-old man received first-line BRAF inhibitor for a T4aN1bM0 ATC. Within 10 days of treatment his pain had stabilized and his tumor had clinically halved in size. Stable disease was achieved for 11 weeks but the patient died 11 months after diagnosis because of disease progression.
    DOI:
    10.6004/jnccn.2016.0030